Both medications have minimal side effects, mostly involving minor digestive upset or injection site reactions
NO-related findings have been explored across multiple tissue and cell-type contexts, including gastrointestinal, endothelial, fibroblast, vascular, and neuronal model systems
The MHRA has not licensed AOD 9604 as a medicinal product in the UK, and its status can be confirmed via the MHRA's product licence search
If 33-merDGP oligomers are formed, they may damage the epithelial cell network, allowing gluten peptides, bacteria, and other toxins to pass massively into the bloodstream, leading to inflammation and, in celiac disease, autoimmunity